Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Fabián P. Alvarez, Pierre Chevalier, Matthias Borms, Hélène Bricout, Catia Marques, Anu Soininen, Tatu Sainio, Christine Petit & Caroline de Courville. (2023) Cost-effectiveness of influenza vaccination with a high dose quadrivalent vaccine of the elderly population in Belgium, Finland, and Portugal. Journal of Medical Economics 26:1, pages 710-719.
Read now
Read now
Eliel Nham, Hye Seong, Hakjun Hyun, Jin Gu Yoon, Ji Yun Noh, Hee Jin Cheong, Woo Joo Kim, Eugene Kim, Leejung Choi, Jung-Min Lee & Joon Young Song. (2023) Cost-effectiveness of high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccine for older people in a country with high influenza vaccination rate. Human Vaccines & Immunotherapeutics 19:3.
Read now
Read now
Articles from other publishers (13)
Maarten Postma, David Fisman, Norberto Giglio, Sergio Márquez-Peláez, Van Hung Nguyen, Andrea Pugliese, Jesús Ruiz-Aragón, Analia Urueña & Joaquin Mould-Quevedo. (2023) Real-World Evidence in Cost-Effectiveness Analysis of Enhanced Influenza Vaccines in Adults ≥ 65 Years of Age: Literature Review and Expert Opinion. Vaccines 11:6, pages 1089.
Crossref
Crossref
Desmond Loong, Ba’ Pham, Mohammadreza Amiri, Hailey Saunders, Sujata Mishra, Amruta Radhakrishnan, Myanca Rodrigues, Man Wah Yeung, Matthew P. Muller, Sharon E. Straus, Andrea C. Tricco & Wanrudee Isaranuwatchai. (2022) Systematic Review on the Cost-Effectiveness of Seasonal Influenza Vaccines in Older Adults. Value in Health 25:8, pages 1439-1458.
Crossref
Crossref
Mark W Tenforde, H Keipp Talbot, Christopher H Trabue, Manjusha Gaglani, Tresa M McNeal, Arnold S Monto, Emily T Martin, Richard K Zimmerman, Fernanda P Silveira, Donald B Middleton, Samantha M Olson, Rebecca J Garten Kondor, John R Barnes, Jill M Ferdinands, Manish M Patel, Shoshona Le, Juliana Da Silva, Lisa M Keong, Thomas J Stark, Joshua G Petrie, Lois E Lamerato, Anurag Malani, Adam Lauring, Ryan E. Malosh, Dayna Wyatt, Yuwei Zhu, Zhouwen Liu, Stephanie Longmire, Kellie Graves, Emily Sedillo, Alina Simion, Karen Speer, Bethany Alicie, Briana Krantz, Donna Carillo, Laura Adams, Amelia Drennan, Jan Orga, Lynn Peterson, Natasha Halasa, Rendi McHenry, Claudia Guevara Pulido, Kempapura Murthy, Kelsey Bounds, Tnelda Zunie, Lydia Clipper, Shekhar Ghamande, Heath White, Chandni Raiyani, Kevin Chang, Arundhati Rao, Manohar Mutnal, Alejandro Arroliga, Mary Patricia Nowalk, K G Balasubramani, Heather Eng, Sean G Saul, Kailey Hughes, Nicole Wheeler, Lori Stiefel, Mohamed Yassin & John V Williams. (2021) Influenza Vaccine Effectiveness Against Hospitalization in the United States, 2019–2020. The Journal of Infectious Diseases 224:5, pages 813-820.
Crossref
Crossref
E. Redondo, I. Rivero-Calle, E. Mascarós, J.E. Yuste, M. Fernández-Prada, D. Ocaña, I. Jimeno, A. Gil, J. Molina, J.L. Díaz-Maroto, M. Linares & F. Martinón-Torres. (2021) Vacunación frente a la neumonía adquirida en la comunidad del adulto. Actualización 2021 del posicionamiento del Grupo de Neumoexpertos en Prevención. Medicina de Familia. SEMERGEN 47:6, pages 411-425.
Crossref
Crossref
Esther Redondo, Georgina Drago, Juan Luis López-Belmonte, Jose María Guillén, Helene Bricout, Fabián P. Alvarez, Daniel Callejo & Ángel Gil de Miguel. (2021) Cost-utility analysis of influenza vaccination in a population aged 65 years or older in Spain with a high-dose vaccine versus an adjuvanted vaccine. Vaccine 39:36, pages 5138-5145.
Crossref
Crossref
Pierre Net, Florian Colrat, Mafalda Nascimento Costa, Florence Bianic, Edward Thommes & Fabián P. Alvarez. (2021) Estimating public health and economic benefits along 10 years of Fluzone® High Dose in the United States. Vaccine 39, pages A56-A69.
Crossref
Crossref
Florian Colrat, Edward Thommes, Nathalie Largeron & Fabián P. Alvarez. (2021) Economic evaluation of high-dose inactivated influenza vaccine in adults aged ≥65 years: A systematic literature review. Vaccine 39, pages A42-A50.
Crossref
Crossref
Melissa K. Andrew & Shelly A. McNeil. (2021) Influenza vaccination and the evolution of evidence-based recommendations for older adults: A Canadian perspective. Vaccine 39, pages A36-A41.
Crossref
Crossref
Elias B. Chahine. (2020) High-Dose Inactivated Influenza Vaccine Quadrivalent for Older Adults. Annals of Pharmacotherapy 55:1, pages 89-97.
Crossref
Crossref
Haley L. Dugan, Carole Henry & Patrick C. Wilson. (2020) Aging and influenza vaccine-induced immunity. Cellular Immunology 348, pages 103998.
Crossref
Crossref
Lee-Jah Chang, Ya Meng, Helene Janosczyk, Victoria Landolfi & H. Keipp Talbot. (2019) Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial. Vaccine 37:39, pages 5825-5834.
Crossref
Crossref
Suleiman Abusrewil, Abdulrahman Algeer, Alanoud Aljifri, Fatima Al Slail, Melissa K. Andrew, Mohamed Awad Tag Eldin, Salah Al Awaidy, Nissaf Ben Alaya, Jalila Ben Khelil, Ghassan Dbaibo, Fawzi Derrar, Omar Elahmer, Nada Ghosn, Guelsah Gabriel, Cindy Grasso, Mohamed Hassan, Siddhivinayak Hirve, Yusuf Kamal Mirza, Yousef Moh'd Rateb, Jalal Nourlil, Marta C. Nunes, Idris Omaima, Oliver Ombeva Malande, Mitra Saadatian‐Elahi, Valentina Sanchez‐Picot, Malik Sk. Mamunur Rahman, Hesham Tarraf & Sibongile Walaza. (2019)
Influenza surveillance in Middle East, North, East and South Africa: Report of the 8th
MENA
Influenza Stakeholders Network
. Influenza and Other Respiratory Viruses 13:3, pages 298-304.
Crossref
Crossref
Melissa K. Andrew, Susan K. Bowles, Graham Pawelec, Laura Haynes, George A. Kuchel, Shelly A. McNeil & Janet E. McElhaney. (2018) Influenza Vaccination in Older Adults: Recent Innovations and Practical Applications. Drugs & Aging 36:1, pages 29-37.
Crossref
Crossref